Wednesday, July 8, 2026

Patent intelligence · US

US 9801894

Steroid compound for use in the treatment of hepatic encephalopathy

granted A61KA61K31/198A61K31/216A61K31/437
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 11
Applicant portfolio 12
Patent details — US 9801894
Jurisdiction
US
Status
granted
Grant date
Oct 31, 2017
Expiration
Oct 26, 2037
Claims
27
CPC classes
A61K, A61K31/198, A61K31/216, A61K31/437
View on Google Patents ↗

Quick answer

US 9801894 (Steroid compound for use in the treatment of hepatic encephalopathy) is held by Umecrine Cognition AB. Status: granted. Granted Oct 31, 2017. Expires Oct 26, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
27
CPC classes
A61K, A61K31/198, A61K31/216, A61K31/437, A61K31/4375, A61K31/568

More from Umecrine Cognition AB

Related pharmaceutical patents in our USPTO index.

  1. US 12208167

    Coated tablets for pH-dependent release of benzgalantamine

    ALPHA COGNITION INC. · Expires Jan 23, 2045

    granted
  2. US 12157743

    Solid forms of Alpha-1062 gluconate

    ALPHA COGNITION INC. · Expires Nov 28, 2044

    granted
  3. US 11795176

    Solid forms of Alpha-1062 gluconate

    ALPHA COGNITION INC. · Expires Oct 19, 2043

    granted
  4. US 11123351

    Pharmaceutical formulation of 3-alpha-ethynyl-3-beta-hydroxyandrostan-17-one oxime

    Umecrine Cognition AB · Expires Sep 16, 2041

    granted
  5. US 10603326

    Pharmaceutical formulation of 3α-ethynyl-3β-hydroxyandrostan-17-one oxime

    Umecrine Cognition AB · Expires Mar 26, 2040

    granted
  6. US 10351589

    3.alpha.-ethynyl, 3.beta.-hydroxy-5.alpha.-pregnan-20-oxime for use in the treatment of CNS disorders

    Umecrine Cognition AB · Expires Jul 11, 2039

    granted
  7. US 10342804

    Steroid compound for use in the treatment of hepatic encephalopathy

    Umecrine Cognition AB · Expires Jul 4, 2039

    granted
  8. US 10278977

    Methods for treating hypersomnolence

    Umecrine Cognition AB · Expires May 2, 2039

    granted

Frequently asked questions

What is US patent 9801894?

US 9801894 (Steroid compound for use in the treatment of hepatic encephalopathy) is held by Umecrine Cognition AB. Status: granted. Granted Oct 31, 2017. Expires Oct 26, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9801894?

Umecrine Cognition AB is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.

When does US 9801894 expire?

Our index shows an expiration date of Oct 26, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.